COVID-19: Mayo Clinic is committed to taking care of our patients, learners and staff. Learn more about attendance requirements for live courses and conferences and available COVID-19 online education and resources.
Foundation Medicine - Exhibitor


 

 

 

 

 

www.foundationmedicine.com

Contact Information:
We are available during business days and hours, feel welcome to call/text/email us as follows:

Suzy Bucher
Cell:  602-317-5102
sbucher@foundationmedicine.com


Mary Anderson
Cell: 480-236-5195
manderson@foundationmedicine.com

Virtual Exhibit Hall Home

 

Our comprehensive genomic profiling tests provide information about clinically relevant biomarkers and genomic alterations to help match patients to approved targeted therapies, immunotherapies, and clinical trial options—giving physicians and patients powerful actionable insights for navigating cancer care. We performed 97% of the sequencing for the pancreatic know your tumor registry trial and are the companion diagnostic test for pemigatinib in patients with FGFR mutations.

Our FDA-approved tissue AND blood-based testing is available for all solid tumors with FoundationOne®CDx and FoundationOne®Liquid CDx. In addition, FoundationOne®Heme is a laboratory developed test for hematologic malignancies, sarcomas, or solid tumors where fusion detection is desired. There is also the option to add on immunohistochemistry (IHC) testing.

An FMI study found that nearly one in five patients with PDAC may be candidates for existing therapies. These patients could be divided into two categories: 1) patients with alterations in kinases signaling, for which many targeted therapies are in development, or 2) patients with alterations in the DNA damage repair pathway, especially the BRCA family of genes, which confer sensitivity to approved chemotherapy regimens and PARP inhibitors.

Researchers have long believed that more than 95 percent of pancreatic cancer patients carry the KRAS gene mutation, but the study found that the number of patients with this mutation is 88 percent.6 Of the 12 percent of patients who have a normal copy of the KRAS gene, a subset instead harbor kinase fusions, for which there are investigational treatments. Larotrectinib, for example, is approved for all tumors that carry the fusions of the genes NTRK1-3. Importantly, these types of alterations can be detected with the breadth and depth provided by CGP testing, as opposed to standard hotspot tests that only test for one or a few genetic mutations.

All testing in our portfolio baits for NTRK 1-3, and other clinically relevant mutations in pancreatic cases.

Please use this link to access the studies we have participated in:
https://www.foundationmedicine.com/blog/uncovering-insights-in-pancreatic-and-prostate-cancers
Additional Information:
https://www.foundationmedicine.com/blog/uncovering-insights-in-pancreatic-and-prostate-cancers

 

Foundation Medicine Matched Therapies in Pancreatic

Foundation Medicine Portfolio

Companion Test for Pemigatinib